BDBM516039 US11053238, Compound 2a::US11053238, Compound 2b

SMILES CN1CCN(CC1)c1ccc(Nc2ncc(F)c(n2)-c2cc(F)c3nc4CCCCn4c3c2)nc1

InChI Key InChIKey=DIFUHKJZJNRRMN-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 516039   

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 4.10nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 108nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 1.90nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 22nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 3.57E+3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 1.68E+3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 596nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 441nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 2.37E+3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 664nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 779nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 649nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent